As patient awareness and knowledge of disease increases, the way in which doctors provide information to their patients in Spain has been changing. In this video, Jorge Sierra, MD, PhD of the Hospital de la Santa Creu i Sant Pau, Barcelona, Spain discusses the way that information is given to patients by clinicians in Spain, how this has changed in recent years and the impacts this has had on patient involement in treatment decision making. This interview was recorded at the International Conference on Acute Myeloid Leukemia 2017, Estoril, Portugal by the European School of Hematology (ESH).
Author: Editor
Myeloproliferative neoplasms are complex diseases, with new research constantly updating our understanding of risk factors that may cause the diseases to develop or certain complications that can arise from them. The Myeloproliferative Neoplasms Advances Day 2017 in London, UK, presented cutting-edge updates in the field. In this interview, Claire Harrison, MD, FRCP, FRCPath, of Guys and St Thomas Hospital NHS Foundation Trust, London, UK, gives an overview of the exciting talks given at the conference, including the TAMARIN study (ISRCTN65011803), prognostic modelling, fresh perspectives on drugs such as warfarin, and the future of genetic sequencing.
For relapsed and elderly acute myeloid leukemia patients, standard treatment is often not good enough. In this interview, Jorge Sierra, MD, PhD of the Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, discusses the alternative treatment options for these patients. Prof. Sierra highlights the importance of these patients being included in clinical trials and recommends alternative options if this is not a possibility. This interview was recorded at the International Conference on Acute Myeloid Leukemia 2017, Estoril, Portugal by the European School of Hematology (ESH).
In this interview, Alessandro Vannucchi, MD, of the University of Florence, Florence, Italy, talks about the new models that doctors can use to determine the prognoses for patients with myeloproliferative neoplasms (MPNs), such as thrombosis for essential thrombocythemia or survival in myelofibrosis patients. Dr Vannucchi highlights how these new models take into account particular mutations, which can affect an individuals chance of reaching a certain endpoint, and can therefore be used by clinicians to assess whether a patient requires a certain therapy, such as stem cell transplantation. This video was recorded at the Myeloproliferative Neoplasms Advances Day 2017 in London,…
An advanced age can limit treatment options when tackling leukemia. Speaking from the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Hematology (ESH), Prof. John DiPersio, MD, PhD of Washington University School of Medicine, Washington, WA discusses treatment options for patients with leukemia who are over the age of 60, and the future applications of chemotherapy and bispecifics in this group.
As alternatives to chemotherapy are created, the prospect of having treatments with a lower toxicity becomes more tangible. In this video, Prof. John DiPersio, MD, PhD from Washington University School of Medicine, Washington, WA provides an insight into how to improve the chances of treating leukemia using bispecifics. Prof. DiPersio discusses when to use bispecifics, and the benefits it will have for patients who have recently undergone transplant or have a positive minimal residual disease status. This video was recorded at the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Haematology (ESH).
This is an exciting time for leukemia research, with the latest research using bispecifics revealing positive outcomes for patients. Here, Prof. John DiPersio, MD, PhD of Washington University School of Medicine, Washington, WA describes future plans to expand a study using bispecifics to treat patients with acute myeloid leukemia. This interview was recorded at the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Haematology (ESH).
The inflammation induced by medication can create challenges when producing novel treatments. In this interview, Prof. John DiPersio, MD, PhD from Washington University School of Medicine, Washington, WA provides an overview of the issue of targeting monocytes in acute myeloid leukemia using CAR T-cells and bispecific agents in terms of cytokine release syndrome. He explains how his team dealt with this issue, and discusses the benefits of using bispecifics compared to CAR T-cells. This interview was recorded at the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Haematology (ESH).
It is crucial that drug toxicity is kept as low as possible to improve the quality of life of patients. Speaking from the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Haematology (ESH), Prof. John DiPersio, MD, PhD of Washington University School of Medicine, Washington, WA discusses using MGD006, a dual-affinity re-targeting agent, to target CD123 in patients with acute myeloid leukemia (AML). He provides an overview on the progress of the ongoing Phase I study (NCT02152956) looking at the toxicity of this drug in patients with relapsed AML and high-risk myelodysplastic syndrome.
As diseases mutate our knowledge of them increases. In this interview, Prof. John DiPersio, MD, PhD from Washington University School of Medicine, Washington, WA explains how the low number of mutations in acute myeloid leukemia affects treatment and research. Prof. DiPersio also touches upon how he utilizes the shared antigen CD123 in his research, its difficulties and why bispecific therapies are useful. This interview was recorded at the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Haematology (ESH).
This is an exciting time for acute myeloid leukemia (AML) treatment, with multiple new therapies being investigated currently. In this interview, Francesco Lo-Coco, MD, from the University Tor Vergata, Rome, Italy discusses recent research using inhibitors for the treatment of AML. This video was recorded at the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Haematology (ESH).
Using uniform methods of detection allows for the efficient diagnosis of various ailments. In this interview, Francesco Lo-Coco, MD, from the University Tor Vergata, Rome, Italy speaks from the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Haematology (ESH). Dr Lo-Coco outlines the method of standardizing molecular diagnostics for patients with myeloid diseases in Italy.
As treatment advancements are made, the number of people who cannot be treated effectively is reduced. In this interview, Francesco Lo-Coco, MD, from the University Tor Vergata, Rome, Italy, discusses the exciting use of second generation inhibitors of FLT3 for acute myeloid leukemia. This interview was recorded at the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Haematology (ESH).
When considering which treatment to prescribe for acute myeloid leukemia (AML), an advanced age is a limiting factor. With recent developments in treatment perhaps this will no longer be the case. In this interview, Andrew Wei, MBBS, PhD, FRACP, FRCPA, from Alfred Hospital and Monash University, Melbourne, Australia discusses the use of BH3 mimetics, such as venetoclax, and immunotherapy drugs for the treatment of elderly patients with AML. Dr Wei also discusses the future applications of mimetics in AML. This video was recorded at the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Hematology…
There have been large strides in the treatment of leukemia; however, current methods lack specificity. Speaking from the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Hematology (ESH), Andrew Wei, MBBS, PhD, FRACP, FRCPA, from Alfred Hospital and Monash University, Melbourne, Australia discusses the use of targeted medication to inhibit anti-apoptotic proteins and how this could reduce toxicity.
Andrew Wei, MBBS, PhD, FRACP, FRCPA, from Alfred Hospital and Monash University, Melbourne, Australia discusses how a novel molecule, S64315, has the potential to combat acute myeloid leukaemia (AML). S64315 has started Phase I trials (NCT02979366) to assess how effective it is against the MCL-1 protein. He also discusses the synergy of using venetoclax and other drugs targeting BCL-2 in combination with drugs targeting MCL-1 to treat AML, and how this could reduce the toxicity of the treatment. This video was recorded at the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Hematology (ESH).
There is some agreement within the multiple myeloma (MM) community regarding the importance of combination chemotherapy, transplant, personalized therapy and minimal residual disease. These hot topics are explored in this intriguing panel discussion at the Myeloma 2017 meeting in Edinburgh, UK by Jonathan Kaufman, MD from Emory University School of Medicine, Atlanta, GA, Faith Davies, MD, MRCP, MRCPath, FRCPath from UAMS Myeloma Institute, Little Rock, AR and Peter Voorhees, MD from the Levine Cancer Institute, Charlotte, NC. The panel also discuss the controversy of treating high-risk smoldering MM patients, and highlight novel studies and combination treatments for MM.
The evasion of apoptosis is a hallmark of cancer, which needs to be halted in order to treat malignancies. In this video, Andrew Wei, MBBS, PhD, FRACP, FRCPA, from Alfred Hospital and Monash University, Melbourne, Australia touches upon the mechanism of apoptosis and the use of venetoclax, a drug that can benefit patients with chronic lymphocytic leukaemia. Dr Wei also discusses his research regarding pro-survival proteins in acute myeloid leukemia. This interview was recorded at the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Hematology (ESH).
As novel anticancer drugs undergo clinical trials and enter the market, patients with cancer are experiencing better outcomes and living longer. However, as outlined in this interview with Verna Lavender, PhD, of Oxford Brookes University, Oxford, UK, patients may develop more complex conditions and comorbidities as they get older, meaning that new drugs may not be suitable until more information is known. This interview was recorded at the UK Oncology Nursing Society (UKON) Annual Conference 2017, held in Harrogate, UK.
Cancer nurses play a critical role in improving the quality of life and outcomes of patients. In this interview, recorded at the UK Oncology Nursing Society (UKONS) Annual Conference 2017, held in Harrogate, UK, Verna Lavender, PhD, of Oxford Brookes University, Oxford, UK, emphasizes how the conference is a great opportunity to show cancer nurses the impact that they can have on patients, and provides networking and educational opportunities.
The UK Oncology Nursing Society (UKONS) Annual Conference 2017, held in Harrogate, UK, had the central theme of person-centered care. Here, Verna Lavender, PhD, of Oxford Brookes University, Oxford, UK talks about what this entails in terms of care and treatment, and provides an overview of the sessions, topics and structure of the conference. Dr Lavender highlights the interactive workshops that were run, including her own, which was dedicated to the development of cancer nurses.
With the NHS being stretched considerably in terms of its budget and increasing pressure placed upon its staff, any strategies that can improve time efficiency and streamline the patient experience are hugely beneficial to both the NHS and the patient. In this interview, Hilary Baker, of University College London Hospitals NHS Foundation Trust, London, UK, outlines the experience of her center in setting up a one-stop multispecialty enhanced recovery clinic for patients undergoing radical cystectomy, highlighting the benefits of this to improving the patient experience as a whole. This interview was recorded at the UK Oncology Nursing Society (UKONS) Annual…
Steven T. Rosen, MD, from the City of Hope, Duarte, CA, discusses the affordability of cancer treatments at the 2017 International Workshop in Non-Hodgkin Lymphoma (iwNHL) in Vancouver, BC, Canada. There are various novel agents being developed, however, current costs make some treatments unaffordable. Therefore, there needs to be negotiations with pharmaceutical companies to bring down the costs, and improve the availability of treatments.
Steven T. Rosen, MD, from the City of Hope, Duarte, CA, discusses novel conceptual treatment approaches at the 2017 International Workshop in Non-Hodgkin Lymphoma (iwNHL) in Vancouver, BC, Canada. A novel nucleoside analogue is being developed that targets RNA instead of DNA has shown promising results in the treatment of AML. Drugs are also being repurposed, for example, arthritis drug leflunomide is being trialled in myeloma, and ritonavir, an HIV drug, is being tested to alter the metabolic activity of leukaemia cells.
Steven T. Rosen, MD, from the City of Hope, Duarte, CA, discusses the evolution of CAR T-cell therapy at the 2017 International Workshop in Non-Hodgkin Lymphoma (iwNHL) in Vancouver, BC, Canada. CAR T-cells have so far shown very promising results, even in relapsed and refractory settings. This therapy is still in its infancy, and therefore there will be continuous improvement in terms of the toxicity profile, and how it is administered. Initially, it has been carried out in specialist centres, however, there is hope that it will evolve into a more common and widespread treatment.
Steven T. Rosen, MD, from the City of Hope, Duarte, CA, discusses recent developments in BTK inhibitors at the 2017 International Workshop in Non-Hodgkin Lymphoma (iwNHL) in Vancouver, BC, Canada. BTK inhibitors have been shown to be effective in CLL, mantle cell lymphoma, Waldenstrom macroglobulinemia, and MALT lymphomas, and are constantly being developed to reduce toxicity. More is also being learned about their resistance mechanisms, and the benefit of combinations.
Steven T. Rosen, MD, from the City of Hope, Duarte, CA, discusses highlights of the 2017 International Workshop in Non-Hodgkin Lymphoma (iwNHL) in Vancouver, BC, Canada. More concrete data had been released for various novel treatments, such as checkpoint inhibitors, CAR T-cell therapies, and ALK inhibitors. Dr Rosen explains that this is a promising and rapidly evolving field, but there are still many challenges ahead.
Michael Pfreundschuh, MD from the Saarland University, Homburg, Germany is joined by Ryan Morin, PhD from the BC Cancer Agency, Vancouver, Canada, Reiner Siebert, MD from the Institute of Human Genetics, University of Kiel, Kiel, Germany, and Robert Kridel, MD, MPH, PhD from the University of Toronto, Toronto, Canada to discuss the clonal evolution in lymphoma. Acting as chair, Dr Pfreundschuh leads to panel to review the sessions highlights from the 2017 International Workshop on Non-Hodgkin Lymphoma (iwNHL) in Vancouver, BC, Canada, focusing on methods of understanding clonal evolution better. The take home message from this discussion is that it…
Anas Younes, MD, from the Memorial Sloan Kettering Cancer Center, New York, NY is joined by Eduardo Sotomayor, MD, from the George Washington University School of Medicine & Health Sciences, Washington, D.C, and Laura Pasqualucci, MD, from the Columbia University Medical Center, New York, NY, at the 2017 International Workshop in Non-Hodgkin Lymphoma (iwNHL) in Vancouver, BC, Canada. They discuss the results of large sequencing studies, and the role of epigenetic modulators in the pathogenesis of lymphomas.
Catherine Bollard, MBChB, MD, FRACP, FRCPA from the Childrens National Health System and the George Washington University, Washington, D.C. chairs a lively discussion on the fast-evolving field of immunotherapy in lymphoma. Dr Bollard is joined by Stephan Ansell, MD, PhD from the Mayo Clinic, MN and Steve Gottschalk, MD from the Baylor College of Medicine, Houston, TX, together they review the immunotherapy session at the 2017 International Workshop on Non-Hodgkin Lymphoma (iwNHL) in Vancouver, BC, Canada. It is an exciting time in lymphoma, with immunotherapies such as CAR T-cells and checkpoint inhibitors showing promising results. Discussing how these could be…
Philippe Gaulard, MD, PhD, from the Henri-Mondor Hospital, Paris, France, Francesco DAmore, MD, PhD, from the Aarhus University, Aarhus, Denmark, Richard Delarue, MD, from the Necker-Enfants Malades Hospital, Paris, France, discuss topics such as recent developments in molecular pathology, results of recent clinical trials, and novel opportunities in personalized medicines in lymphoma at the 2017 International Workshop in Non-Hodgkin Lymphoma (iwNHL) in Vancouver, BC, Canada.
Patients with myeloproliferative neoplasm (MPNs) are at a higher risk of mortality due to thrombosis compared with unaffected individuals. Speaking from the Myeloproliferative Neoplasms Advances Day 2017 in London, UK, Tiziano Barbui, MD, from Hospital Papa Giovanni XXIII, Bergamo, Italy, discusses this issue and highlights the efforts being made to combat it, including cytoreductive therapy and anticoagulants. Prof. Barbui then provides an overview of his groups exciting ongoing studies, which are collecting data from over 1,000 MPN patients.
In this interview, recorded at the Myeloma 2017 meeting in Edinburgh, UK, Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM, from University College London, London, UK, talks to us about the most anticipated upcoming trial results in the treatment of amyloidosis to be released at ASH 2017, including genetic data exploring the effect of translocations such as t(11;14) upon a patients response to bortezomib, and the addition of bortezomib to a combined therapy regimen of melphalan and dexamethasone.
Around a quarter of new amyloidosis patients die within 6 months of diagnosis, and, despite large pharmacological and technological advancements, this statistic has not improved over the past three decades. Here, Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM, from University College London, London, UK, highlights two of the primary requirements of future amyloidosis research in order to reduce this mortality rate. Dr Wechalekar emphasizes the need to improve awareness of the disease in primary care settings to increase the speed of diagnosis. This video was recorded at the Myeloma 2017 meeting in Edinburgh, UK.
There are two primary routes of therapy for amyloidosis: treating the underlying plasma cell dyscrasia, and clearing amyloid deposits. In this insightful interview, recorded at the Myeloma 2017 meeting in Edinburgh, UK, Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM, from University College London, London, UK, gives an overview of some of the most exciting data in the field, including bortezomib combinations, single agent daratumumab, and ixazomib, which have shown great potential. Dr Wechalekar highlights ongoing studies of monoclonal antibodies that act through clearing amyloid deposits, including a highly anticipated anti-SAP antibody being developed (NCT03044353), and NEOD001, currently being investigated in…
Key to the treatment of amyloidosis is being able to discern the severity of illness, so that the patient can be prescribed an appropriate therapy course. In this interview, Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM, from University College London, London, UK, discusses the latest advancements in patient risk stratification, new imaging agents to observe amyloid deposits in soft tissues, and novel treatments for the condition. These include the recent monitoring of von Willebrand factor as a prognostic marker, and immunotherapy drugs currently in clinical trials. This video was recorded at the Myeloma 2017 meeting in Edinburgh, UK.
Prostate cancer therapies have developed greatly in recent years, with many more options for treatment available that can provide patients with a higher quality of life for years after diagnosis. Here, Hilary Baker of University College London Hospitals NHS Foundation Trust, London, UK, summarizes the current strategies available to prostate cancer patients. This interview was recorded at the UK Oncology Nursing Society (UKONS) Annual Conference 2017 in Harrogate, UK.
A clinical nurse specialist plays a critical role in the treatment of a cancer patient. In this interview, Hilary Baker of University College London Hospitals NHS Foundation Trust, London, UK, gives an overview of her talk at the UK Oncology Nursing Society (UKONS) Annual Conference 2017, Harrogate, UK, where she discussed the role of the CNS in mCRPC treatment, and the unique nature of the position as both a clinical assessor and a provider of psychological support to the patient.
Nathan Fowler, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, discusses side effects of PI3K inhibitors at the 2017 International Workshop in Non-Hodgkin Lymphoma (iwNHL) in Vancouver, BC, Canada. Transaminitis is where transaminases are elevated in the liver. This usually occurs at the start of treatment, and has been found to go away once stopping and restarting treatment. Other side effects include inflammatory conditions, such as colitis and pneumonitis. It is recommended that patients who present with these side effects stop treatment, and undergo an infectious workup.
Idelalisib was the first phosphoinositide 3-kinase (PI3K) inhibitor to be used in lymphoma, which had remarkable responses on B-cell lymphomas as a single-agent. Nathan Fowler, MD at the University of Texas MD Anderson Cancer Center, Houston, TX talks about the different combination studies with idelalisib, and how we are trying to overcome toxicities found, by developing second-generation PI3K inhibitors, such as copanlisib, umbralisib, and duvelisib. Recorded at the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2017 annual meeting, held in Vancouver, BC, Canada.
Marek Trneny, MD, from the Charles University, Prague, Czech Republic, discusses highlights from the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2017, held in Vancouver, BC, Canada. The PDX model in particular is important in terms of drug discovery and testing, and better understanding the mechanism of the disease and drug action.
John Kuruvilla, MD, FRCPC, from the Princess Margaret Cancer Centre, Toronto, Canada, discusses integrating treatments around autologous transplantation at the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2017, held in Vancouver, BC, Canada. Phase III trials have shown that autologous transplantation is superior to conventional chemotherapy, however, more research needs to be carried out to determine how to integrate novel therapies around transplant, because a large proportion of patients dont respond to treatment before transplant. This has been successful in Hodgkin lymphoma so far, however, this has not been mirrored in non-Hodgkin lymphoma. CAR T-cell therapy has been shown to have…
John Kuruvilla, MD, FRCPC, from the Princess Margaret Cancer Centre, Toronto, Canada, discusses the development of IMiDs at the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2017, held in Vancouver, BC, Canada. IMiDs have been shown to have single agent activity, particularly in lymphoma and myeloma. A novel compound being developed for diffuse large B-cell lymphoma is called CC122, shown to be well tolerated, and its administered as orally. It has also been tested in combination with a BTK inhibitor, an MTOR inhibitor, and with anti CD20 antibodies in the relapsed refractory setting. These will hopefully be put through Phase III…
The exciting field of proton beam therapy is still developing; thus, as its utilization in the UK increases there is a need for further research to ensure that it is used effectively and appropriately. Speaking from the 2017 National Cancer Research Institute (NCRI) Conference in Liverpool, UK, Anthony Zietman, MD, from the Massachusetts General Hospital, Boston, MA, discusses the current usage of proton beam radiation as a treatment for cancer within the UK, the benefits of this in terms of cost-saving and what further research is required moving forwards.
The introduction of new healthcare tools requires the careful navigation of social, political and economic pressures. In this interview, recorded at the 2017 National Cancer Research Institute (NCRI) Conference in Liverpool, UK, Anthony Zietman, MD, from the Massachusetts General Hospital, Boston, MA, discusses the challenges that were faced when establishing two UK centers for proton beam therapy. Dr Zietman also details the future questions that need to be explored regarding proton therapy. Furthermore, Dr Zietman provides an overview of the model of patient selection used for Denmarks emerging proton therapy system.
The uptake of proton beam therapy has been slower in the UK compared with other developed countries; however, this is now set to change. In this insightful interview, Anthony Zietman, MD, from the Massachusetts General Hospital, Boston, MA, discusses the future of proton beam therapy in the UK, highlighting affordability, as well as the ability of the UK to integrate any successor of proton beam therapy. This interview was recorded at the 2017 National Cancer Research Institute (NCRI) Conference, held in Liverpool, UK.
Since 2004, over 20 new proton beam centers, a type of radiation primarily identified as being effective in treating pediatric cancers, have been built in the USA. In this interview, Anthony Zietman, MD, from the Massachusetts General Hospital, Boston, MA, discusses how PSA testing and the increase in the number of men diagnosed with prostate cancer contributed to this. Dr Zietman highlights how the financial model in the USA is seeing this market quickly declining again. However, the UK has recently emerged with plans for two proton beam centers, which could provide the required evidence for the use of the…
Radiation therapy is well established as one of the three primary approaches to treating cancer; however, it comes with a number of issues. Here, Anthony Zietman, MD, of the Massachusetts General Hospital, Boston, MA, discusses these issues, and describes the pros and cons of proton beam therapy in comparison to standard radiotherapy, particularly in a pediatric setting. This video was recorded at the 2017 National Cancer Research Institute (NCRI) Conference, held in Liverpool, UK.
CAR-T cell therapy is an innovative new strategy that may revolutionize lymphoma treatment. Speaking from the 2017 National Cancer Research Institute (NCRI) Conference in Liverpool, UK, Graham Collins, MA, MBBs, MRCP, FRCPath, DPhil of the Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the effectiveness of CAR-T cell therapy in relapsed and refractory lymphoma, and reviews some of the pros and cons that may arise from the usage of CAR-T cells, including cost, ease of administration and toxicity.
New studies are constantly evolving the field of lymphoma research, with trials continuously striving to find more effective treatments. At the 2017 National Cancer Research Institute (NCRI) Conference in Liverpool, UK, Graham Collins, MA, MBBs, MRCP, FRCPath, DPhil of the Oxford University Hospitals NHS Foundation Trust, Oxford, UK, spoke to us about some of the most anticipated upcoming trial results in the field of lymphoma treatment. Among them include the ECHELON-1 trial (NCT01712490), comparing ABVD with AVD plus brentuximab vedotin in the treatment of advanced stage Hodgkin lymphoma, and the new antibody-drug conjugate ADCT-301, which targets CD25. Dr Collins reviews…